Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop IRD Treatment
Massachusetts Eye and Ear is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common cause for autosomal dominant retinitis pigmentosa. Previous lab-based...